You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 29, 2024

Claims for Patent: 8,703,150


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,703,150
Title:Methods of using Bacillus anthracis protective antigen sequences for vaccination
Abstract: The invention relates to improved methods of producing and recovering B. anthracis protective antigen (PA), especially modified PA which is protease resistant, and to methods of using of these PAs or nucleic acids encoding these PAs for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, B. anthracis bacterial infections and which are useful to prevent and/or treat illnesses caused by B. anthracis, such as inhalation anthrax, cutaneous anthrax and gastrointestinal anthrax.
Inventor(s): Leppla; Stephen H. (Bethesda, MD), Schneerson; Rachel (Bethesda, MD), Robbins; John B. (New York, NY)
Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services (Washington, DC) N/A (N/A)
Application Number:13/244,060
Patent Claims:1. A method for vaccinating a human against B. anthracis infection, comprising administering to the human an immunizing amount of a vaccine composition comprising a modified Bacillus anthracis (B. anthracis) protective antigen, wherein the antigen comprises a B. anthracis protective antigen shown in SEQ ID NO: 3 modified such that the amino acid sequence RKKR.sup.167 (SEQ ID NO: 14) has been changed to SNKE.sup.167 (SEQ ID NO: 15), the two phenylalanines at positions 313-314 are deleted, and the glutamic acid at position 308 is substituted with aspartic acid.

2. The method of claim 1, wherein the vaccine composition further comprises a physiologically acceptable carrier and aluminum hydroxide.

3. The method of claim 1, wherein the vaccine composition further comprises a physiologically acceptable carrier.

4. The method of claim 3, wherein the physiologically acceptable carrier comprises saline or phosphate-buffered saline.

5. The method of claim 1, wherein the vaccine composition further comprises an adjuvant.

6. The method of claim 5, wherein the adjuvant comprises aluminum hydroxide.

7. The method of claim 1, wherein the vaccine composition further comprises formalin.

8. The method of claim 1, wherein the vaccine composition further comprises an adjuvant and formalin.

9. The method of claim 1, wherein the B. anthracis protective antigen that has been modified comprises the amino acid sequence shown in SEQ ID NO: 4.

10. The method of claim 1, wherein the B. anthracis protective antigen that has been modified consists of the amino acid sequence shown in SEQ ID NO: 4.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.